ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Rugo on Anti-Angiogenesis Therapy Response Predictors

Hope S. Rugo, MD
Published: Wednesday, Sep 07, 2011

Hope S. Rugo, MD, clinical professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology Clinical Trials Program, University of California, San Francisco, discusses the need for further development and investigation into response and resistance predictors of anti-angiogenesis therapy in breast cancer.

Some agents that block angiogenesis, such as bevacizumab (Avastin), are known to have an effect but an adequate method of predicting resistance and which breast cancer tumors will respond still needs to be investigated.

Rugo explains that active trials are underway examining predictive factors such as the use of host genomics to predict toxicity and response. At this point due to the complicated nature of host genetics it may be better used as a predictor of toxicity rather than for efficacy. Many of these pharmacogenetics or polymorphisms of genes that were discovered in the ECOG 2100 trial examining metastatic breast cancer are now being investigated in the adjuvant trial ECOG 5103.
Hope S. Rugo, MD, clinical professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology Clinical Trials Program, University of California, San Francisco, discusses the need for further development and investigation into response and resistance predictors of anti-angiogenesis therapy in breast cancer.

Some agents that block angiogenesis, such as bevacizumab (Avastin), are known to have an effect but an adequate method of predicting resistance and which breast cancer tumors will respond still needs to be investigated.

Rugo explains that active trials are underway examining predictive factors such as the use of host genomics to predict toxicity and response. At this point due to the complicated nature of host genetics it may be better used as a predictor of toxicity rather than for efficacy. Many of these pharmacogenetics or polymorphisms of genes that were discovered in the ECOG 2100 trial examining metastatic breast cancer are now being investigated in the adjuvant trial ECOG 5103.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x